Benzinga | Dec 17, 2021 07:17AM EST

Cantor Fitzgerald Initiates Coverage On Cardiol Therapeutics with Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald analyst Charles Duncan initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Overweight rating and announces Price Target of $8.